Systems and methods for embolization procedures for treatment of defects in the vasculature
AssigneeDePuy Synthes Products, Inc.
InventorsEmilie Kottenmeier, Shelly Ikeme, Rahul Khanna, Xiaozhou Fan, Sudhakar Satti
Life of this patent
Estimating the term…
Abstract
Methods and systems including an N-butyl cyanoacrylate (“n-BCA”) liquid embolic agent and achieving, by the n-BCA liquid embolization agent, a reduction in total cost of preoperative embolization procedures for a plurality of patients versus an ethylene vinyl alcohol copolymer (“EVOH”) liquid embolic agent. Methods and systems for reducing supply costs of preoperative embolization by at least approximately 18% are described.
Claims24
A method or use of reducing a cost of embolization in a human patient at risk for intracranial hemorrhage, the method comprising:
- calculating a cost adjusted ratio for embolizing at least one blood vessel adjacent a vascular tangle in a first group of human patients with a first embolic agent comprising N-butyl cyanoacrylate (the “n-BCA”) compared to embolizing at least one blood vessel adjacent a vascular tangle in a second group of human patients with a second embolic agent, wherein the cost adjusted ratio comprises conditions comprising at least one of:
- embolization procedure time,
- units of first or second embolic agent,
- concentration per unit of first or second embolic agent,
- type of catheter,
- number of catheters, and
- angiography suite time;
- identifying at least one condition in the cost adjusted ratio to achieve at least 18% reduced cost of the embolization of the first group compared to the second group,
- the cost adjusted ratio being determined by a Generalized estimating equations (GEE) model;
- and
- embolizing, by a first catheter, by delivering the n-BCA, adjusted by at least one condition, within at least one blood vessel adjacent a vascular tangle in a respective human patient.
A method or use of reducing a cost of embolization in a human patient at risk for intracranial hemorrhage based on a comparison of costs for embolizing a first group of human patients compared to a second group of human patients treated with disparate embolic agents, the method comprising:
- comparing cost conditions of embolizing, the cost conditions comprising at least one of:
- embolization procedure time,
- units of a first embolic agent or a second embolic agent,
- concentration of the first embolic agent or the second embolic agent per unit,
- type of catheter,
- number of catheters, and
- angiography suite time;
- and
- reducing embolization procedure time while maintaining hospital length of stay by embolizing, by a first catheter, by delivering the first embolic agent comprising N-butyl cyanoacrylate (the “n-BCA”) within at least one blood vessel adjacent a vascular tangle in a respective human patients.
A method or use comprising:
- determining a ratio of cost conditions of embolizing a first group of human patients treated with a first embolic agent comprising N-butyl cyanoacrylate (the “n-BCA”) compared to a second group of human patients treated with a second embolic agent comprising ethylene vinyl alcohol copolymer (the “EVOH”), the ratio of cost conditions comprising comparing n-BCA to EVOH for at least one of embolization procedure time, units of embolization agent, concentration of embolization agent per unit, type of catheter to deliver embolization agent, number of catheters to deliver embolization agent, and angiography suite time;
- and
- delivering, by a first catheter, the n-BCA, adjusted by at least one condition, within at least one blood vessel adjacent a vascular tangle of a respective human patient to achieve a reduced total cost of the embolization procedure in the respective human patient.
A method or use of reducing a cost of embolization in a patient at risk for intracranial hemorrhage, the method comprising:
- calculating a cost adjusted ratio for a condition comprising at least one of embolization procedure time, units of a first or second embolization agent, concentration of the first or second embolization agent per unit, type of catheter, number of catheters, and angiography suite time between a first group of human patients treated with the first embolic agent compared to a second group of human patients treated with a second embolic agent;
- delivering, by a first catheter, the first embolic agent within at least one blood vessel adjacent a vascular tangle of a respective human patient;
- and
- reducing at least one condition to achieve a difference in cost of preoperative embolization procedure for the respective human patient from approximately 30% to approximately 57%, by the first embolic agent,
- wherein the first embolic agent comprises N-butyl cyanoacrylate (the “n-BCA”) and the second embolic agent comprises ethylene vinyl alcohol copolymer (the (“EVOH”).
Dependencies are inferred from the claim text.